Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
This post hoc analysis assessed the evidence behind common reimbursement practices by evaluating the relationship of body mass index (BMI) ranges (<30, 30–35 and >35 kg/m2) with treatment effects of exenatide twice daily among patients with type 2 diabetes. Patients received exenatide twice da...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Blackwell Publishing Ltd
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111732/ |